New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
08:00 EDTTEVA, MNTA, HITK, RDY, MNK, ACT, PRGO, IPXLBMO Capital to hold a summit
BMO Generic Drug Summit is being held in Orlando on February 19.
News For ACT;HITK;IPXL;MNK;MNTA;PRGO;RDY;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 8, 2015
11:52 EDTMNTAMomenta downgraded to Neutral from Buy at UBS
Subscribe for More Information
11:51 EDTPRGOPerrigo calls active on Mylan proposal to acquire for $205 per share
Subscribe for More Information
11:45 EDTPRGOMylan volatility up after proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:40 EDTPRGOPerrigo up $47.10 to $211.81, trading above Mylan's $205/share proposal
Subscribe for More Information
11:35 EDTPRGOGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
Subscribe for More Information
11:34 EDTPRGOGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
11:32 EDTPRGOMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:31 EDTPRGOPerrigo halted for volatility after jumping 7% to $176.42
Subscribe for More Information
11:29 EDTPRGOMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
10:01 EDTIPXLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:16 EDTACTActavis COPD drug Daliresp gets Paragraph 4 challenge
Subscribe for More Information
08:56 EDTPRGO, MNKPerrigo's ANDA for equivalent of Mallinckrodt's Exalgo approved by FDA
Subscribe for More Information
08:05 EDTACTActavis price target raised to $348 from $328 at Leerink
Subscribe for More Information
08:04 EDTACTActavis potential acquisition Rhythm initiates Phase 2b study of relamorelin
Subscribe for More Information
07:34 EDTACTActavis initiates Phase 2b clinical trial of relamorelin
Subscribe for More Information
07:16 EDTTEVAMylan one of the cheapest names in Specialty Pharma, says JPMorgan
Subscribe for More Information
05:10 EDTRDYDr. Reddy's Labs files three NDAs with FDA
Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, announced the filing of three 505(b)(2) New Drug Applications, or NDAs, with the FDA. The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in dermatology and neurology. DFD-01 and DFD-09 are the first dermatology applications submitted to the NDA that have been fully developed leveraging in-house capabilities. DFD-01 is a corticosteroid delivered in a novel non-irritating spray platform, intended for the treatment of patients suffering from psoriasis. DFD-09 is a modified release oral tetracycline intended for the treatment of rosacea. DFN-11 is the first development program filed in support of a newly created vertical, focused on the U.S. neurology market. DFN-11 is a drug-device combination product intended to treat acute migraine episodes in certain patient populations who are inadequately managed with existing treatment regimens.
April 7, 2015
16:11 EDTIPXLImpax initiated with a Hold at Deutsche Bank
Subscribe for More Information
15:24 EDTTEVATeva price target raised to $75 from $64 at BMO Capital
BMO Capital raised its EPS estimates for Teva (TEVA) and increased its price target on the stock to $75 from $64 on account of the expected launch of a treatment for chorea associated with Huntington’s disease in 3Q16 and a launch of a tardive dyskinesia drug in 3Q17 following the company's deal to buy Auspex (ASPX). The firm maintains its Outperform rating on Teva shares.
06:43 EDTIPXLImpax price target raised to $58 from $49 at Piper Jaffray
Piper Jaffray raised its price target for Impax Laboratories to $58 saying retail prescription data shows the company's generics business is "quietly performing well." Piper believes revenue from the generics segment could outperform its expectations for 2015 and also drive "significant"growth longer-term. It reiterates an Overweight rating on Impax.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use